Nutriband, Inc. NTRB 深 沪
等待开盘 11-05 09:30:00 美东时间
5.78
-0.440
-7.07%
华盛通- 最 高6.31
- 今 开6.10
- 成交量 4.25万股
- 最 低 5.6934
- 昨 收 6.22
- 总市值 6956.17万
- 52周最高 11.78
- 市盈率 静 --
- 换手率 0.35%
- 52周最低 3.7223
- 委 比 41.34%
- 总股本 1203.49万
- 历史最高 11.78
- 量 比 0.45
- 振 幅 9.91%
- 历史最低 1.53
- 每 手 1
- 风险率 1.32%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Nutriband Announces Successful Meeting Completed With United States FDA For Its Abuse Deterrent Fentanyl Patch
<p>Nutriband met with the US FDA to discuss the Chemistry, Manufacturing, and Controls plans for its abuse-deterrent fentanyl patch, AVERSA™ FENTANYL. The FDA provided feedback on the regulatory pathway, manufacturing strategy, product specifications, and abuse-deterrent studies. Nutriband is incorporating this feedback into its development program ahead of an IND filing for a Human Abuse Potential clinical study. AVERSA™ combines Nutriband's abu...
10-28 11:00
Nutriband Founder Gareth Sheridan Returns as CEO to Lead Company Toward 2026 NDA Filing, Serguei Melnik Steps Down
Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) has announced that Company founder, Gareth Sheridan has returned as Company CEO. During the period of August 10 until October 27 , Co-Founder and Chairman, Serguei
10-27 19:09
Nutriband Signs Agreement With Brand Institute to Develop the Commercial Brand Name for Its Abuse Deterrent Fentanyl Patch
Nutriband has partnered with Brand Institute to develop a worldwide commercial brand name and visual identity for its lead product, an abuse-deterrent fentanyl transdermal system. This product utilizes Nutriband’s AVERSA™ abuse deterrent transdermal technology, which incorporates aversive agents into transdermal patches to prevent abuse, misuse, and accidental exposure of opioids. Brand Institute, a global leader in pharmaceutical brand naming, w...
10-10 11:00
Nutriband Files Provisional Patent Application for Enhanced Transdermal Abuse Deterrent Technology
Nutriband filed a provisional patent application to enhance its AVERSA™ abuse-deterrent transdermal technology for opioid and stimulant patches. The technology uses aversive agents to prevent misuse, diversion, and accidental exposure, with existing patents in 46 countries. This new application aims to strengthen intellectual property protection and potentially extend patent coverage. AVERSA™ helps improve the safety profile of transdermal drugs ...
10-08 12:30
Nutriband To Present at the Noble Capital Markets’ Emerging Growth Virtual Equity Conference
Nutriband Inc.'s Chairman, Serguei Melnik, is set to present at Noble Capital Markets' Emerging Growth Virtual Equity Conference on October 8, 2025, at 3:00 PM Eastern Time. The event will feature a fireside Q&A session and 1x1 meetings with investors. A live webcast will be available, with an archive on Channelchek.com for 90 days. Nutriband highlights its AVERSA™ technology, designed to deter abuse of transdermal drugs, particularly opioids.
10-08 10:30
Nutriband Inc. to Present at the MicroCap Rodeo Conference
Nutriband Inc. will participate in the MicroCap Rodeo Conference on Thursday, September 25, 2025, in New York City. Company Chairman Serghuei Melnik will discuss the company's operational highlights, growth initiatives, and strategic direction for its AVERSA abuse-deterrent technology. The presentation will be live at 10AM and available for virtual viewing. The conference will feature group presentations, one-on-one meetings with investors, indus...
09-24 20:05
Nutriband Q2 Adj. EPS $(0.18) Misses $(0.17) Estimate, Sales $622.452K Miss $705.000K Estimate
Nutriband (NASDAQ:NTRB) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.17) by 5.88 percent. This is a 20 percent decrease over losses of $(0.15) per share from the same
09-10 22:05
Nutriband's six month revenue jumps 51% YY
Nutriband (NASDAQ:NTRB) produced a record six months reporting revenue of $1.29M, up 50.87% YOY, the company said on Wednesday. As of July 31, 2025, Nutriband’s cash reserves stood at $6.9 million, th...
09-10 21:34
Nutriband Reports 50.87% Revenue Growth, $6.9M Cash; Advances AVERSA Fentanyl Toward NDA With No Phase 2/3 Trials Required
Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) reported its financial results for the six months ended July 31, 2025. The company reported a strong cash position at quarter end, reinforcing its ability to advance the
09-10 21:20
Nutriband Issues Shares Amid Investor Engagement
Nutriband ( ($NTRB) ) has issued an announcement. Between February 1 and July 3...
09-04 01:28
